title: The impact of inoperable advanced basal cell carcinoma: the economic, physical, and psychological burden of the disease.
abstract: The development of vismodegib and its recent approval by the United States Food and Drug Administration for use in patients with locally advanced or metastatic basal cell carcinoma (BCC) carries with it a renewed sense of optimism. Once BCC has progressed to an advanced, or so-called inoperable stage, there has been a paucity of effective therapies, making the new small molecule inhibitors targeting the hedgehog pathway particularly hopeful prospects. In order to better understand the utility of these new treatments, it is important to assess the existing economic, physical, and psychological burden of advanced BCC. This review aims to recognize the impact of inoperable and metastatic BCC, as well as to better characterize the various types of advanced BCC. The use of vismodegib as a prophylactic treatment in patients with basal cell nevus syndrome is also addressed, including possible adverse events, tumor resistance, and new onset malignancies.
authors.forename: Arielle W
authors.initials: AW
authors.lastname: Haves
authors.forename: Panta Rouhani
authors.initials: PR
authors.lastname: Schaffer
authors.forename: John A
authors.initials: JA
authors.lastname: Carucci
mesh_terms: D000813:Anilides / Q000627:therapeutic use; D001478:Basal Cell Nevus Syndrome / Q000175:diagnosis / Q000191:economics / Q000503:physiopathology / Q000523:psychology; D014408:Biomarkers, Tumor; D002280:Basal Cell Carcinoma / Q000191:economics* / Q000503:physiopathology / Q000523:psychology*; D017281:Cost of Illness; D003937:Diagnosis, Differential; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000191:economics* / Q000503:physiopathology / Q000523:psychology*
chemical_list: D000813:Anilides; D014408:Biomarkers, Tumor; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines